Fresenius Medical Care AG & Co. (ADR) (FMS)

follows the market~~

5 Star, Small Cap- pays dividend

Renal failure is not an optional program. If a patient needs dialysis they have the market. The alternate is a transplant, not always available, or embalming, which is not a preferred choice in most cases.

A worldwide leader in kidney dialysis machines and services. Unfortunately (healthwise) a growth industry. Somewhat high debt is a concern, but quite manageable with the company's otherwise strong financials.

Dialysis treatment will continue to expand

Growth, and value at this level. New 52 week low.

So, you think you'll put off that kidney dialysis because of the poor economy??

IBD

Regular profit gain over last several years continued through 2008. Expect improving profits to continue with expanding health care.

Because cramer and the all stars said

IS A PLUS

My company is working on the expansion of the Fresenius site in Ogden, Utah. In the simplest terms, there are now six lines producing the "fibers" used in the dialysis equipment. There are more lines to come, oh yes, there are more....which means there will be more production. This company is only growing, and I know this from first hand experience.

I've never been good at picks in the medical sector. I like this company for its investment in Renal Solutions, since I can't buy into Renal solutions directly. Here's a blurb about Renal Solutions:

The nature of our new approach -- using living cells as therapeutic agents -- argues for the feasibility of developing whole classes of new cell-based and tissue engineered therapies. The ability to harness vital processes of cells, to target their living molecular machinery on restoring critical substances which have become disordered by disease, has vast implications for the future of medicine. The apparently successful use of living cells in this way validates our approach and should encourage others to investigate cell therapies for a range of disorders.

MOre services for the aging population. And the government still pays for dialysis; if they stop (not a chance) this stock may tank.

FMS provided kidney dialysis services and products to over 26 countries. The company has been expanding its business, acquiring dialysis providers in 2003 & 2006. The company improved its revenue growth, EPS and net income, gross profit margin and net cash flow in the most recent quarter when compared to the same quarter last year. The company does need to work on improving its liquidity. However, they should continue to improve financially in all areas over the next year.

I work at a subsidiary of FMS, Spectra Labs. I have no inside info on financials But I like this company and its mission. They treat empolyees well and although we profit from the illness of others we provide important care to them. Our future has never seemed brighter!

Fresenius Medical is well positioned to benefit from its strong market position as a dialysis care provider and product maker. Not only is it the US market leader, it also is growing fast in emerging markets which see rising need for dialysis services.
The company's business model is not exposed to fluctuations in economic growth, and a recent de-rating of its multiples make the stock look like an interesting investment in the longer term.

Breaking out to new all time highs after a short period of consolation. Great play on the aging baby boomers and rise in Type II diabetes in this country (sorry for sounding like a rapacious capitalists). Expecting this stock to hit $60 by the end of the year and placing stop loss below the 200 Day Moving Average.

my #.1, 20 to 30% per year